Black Rock Inc. Clearside Biomedical, Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 758,226 shares of CLSD stock, worth $985,693. This represents 0.0% of its overall portfolio holdings.

Number of Shares

758,226

Previous 759,743 0.2%

Holding current value

$985,693

Previous $888,000 30.63%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$1.2 - $2.02 $1,820 - $3,064	-1,517 Reduced 0.2%	758,226 $1.16 Million
Q4 2023 Feb 13, 2024	SELL	$0.68 - $1.18 $2,372 - $4,117	-3,489 Reduced 0.46%	759,743 $888,000
Q3 2023 Nov 13, 2023	SELL	$0.82 - $1.27 $41,063 - $63,599	-50,078 Reduced 6.16%	763,232 $664,000
Q2 2023 Aug 11, 2023	BUY	$0.97 - $1.48 $14,345 - $21,887	14,789 Added 1.85%	813,310 $910,000
Q1 2023 May 12, 2023	SELL	$0.93 - $1.66 $632 - $1,128	-680 Reduced 0.09%	798,521 $830,000

Q4 2022 Feb 13, 2023	SELL	$1.0 - $1.5 $390,748 - $586,122	-390,748 Reduced 32.84%	799,201 $895,000
Q3 2022 Nov 14, 2022	SELL	$1.13 - $1.83 $26,039 - $42,170	-23,044 Reduced 1.9%	1,189,949 $1.35 Million
Q2 2022 Aug 12, 2022	SELL	$1.3 - $2.49 $8,026 - $15,373	-6,174 Reduced 0.51%	1,212,993 $1.78 Million
Q1 2022 May 12, 2022	SELL	$1.35 - $2.88 $299 - $639	-222 Reduced 0.02%	1,219,167 $2.79 Million
Q4 2021 Feb 10, 2022	BUY	$2.72 - $5.72 $1.13 Million - $2.37 Million	415,037 Added 51.6%	1,219,389 $3.35 Million
Q3 2021 Nov 09, 2021	BUY	$4.83 - $7.2 $158,395 - $236,116	32,794 Added 4.25%	804,352 $4.83 Million
Q2 2021 Aug 11, 2021	BUY	$2.32 - $5.38 $1.79 Million - $4.15 Million	771,558 New	771,558 $3.76 Million

Others Institutions Holding CLSD

# of Institutions

Shares Held

15.1M

Call Options Held

22.7K

Put Options Held

200

View Full List

About Clearside Biomedical, Inc.

Ticker CLSD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,190,700
Market Cap $78.2M
Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...

More about CLSD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account